KemPharm (NSDQ:KMPH) said yesterday it inked a collaborative licensing deal with KVK Tech to obtain U.S. commercial rights to the company’s FDA-approved Apadaz drug. Through the agreement, KemPharm is eligible to receive approximately $3.4 million in pre-launch payments and core cost reimbursement, including a $2 million milestone payment “related to the initial formulary adoption of Apadaz. […]